In Vitro and In Vivo Antimalarial Activities of T-2307, a Novel Arylamidine

T-2307, a novel arylamidine, has been shown to exhibit broad-spectrum antifungal activities against clinically significant pathogens. Here, we evaluated the in vitro and in vivo antimalarial activity of T-2307. The 50% inhibitory concentrations (IC(50)s) of T-2307 against Plasmodium fakiparum FCR-3 and K-1 strains were 0.47 and 0.17 mu M, respectively. T-2307 at 2.5 to 10 mg/kg of body weight/day exhibited activity against blood stage and liver stage parasites in rodent malaria models. In conclusion, T-2307 exhibited in vitro and in vivo antimalarial activity.